Supernus Pharmaceuticals reported $144.71M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Abbott USD 6.95B 419M Jun/2025
ANI Pharmaceuticals USD 217.8M 67.99M Jun/2025
Aurora Cannabis CAD 140.16M 31.45M Jun/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Canopy Growth CAD 126.2M 109.89M Jun/2025
Corcept Therapeutics USD 102.74M 12.93M Jun/2025
Eisai JPY 285.38B 19.82B Jun/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
Novo Nordisk A/S 18.44B 5.78B Jun/2025
Pacira USD 300.48M 16.87M Jun/2025
Perrigo USD 454.2M 44.3M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
Supernus Pharmaceuticals USD 144.71M 28.86M Jun/2025
United Therapeutics USD 1.59B 306.8M Jun/2025
Xeris Pharmaceuticals USD 59.28M 12.34M Jun/2025